213 related articles for article (PubMed ID: 3707802)
1. Static v. dynamic tests in the in vitro diagnosis of malignant hyperthermia susceptibility.
Ranklev E; Fletcher R; Blomquist S
Br J Anaesth; 1986 Jun; 58(6):646-8. PubMed ID: 3707802
[TBL] [Abstract][Full Text] [Related]
2. In vitro diagnosis of susceptibility to malignant hyperthermia: comparison between dynamic and static halothane and caffeine tests.
Ording H; Skovgaard LT
Acta Anaesthesiol Scand; 1987 Jul; 31(5):458-61. PubMed ID: 3630590
[TBL] [Abstract][Full Text] [Related]
3. Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia.
Ording H; Bendixen D
Eur J Anaesthesiol; 1992 Sep; 9(5):367-76. PubMed ID: 1396623
[TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
[TBL] [Abstract][Full Text] [Related]
6. Use of the calcium agonist BAY K 8644 for in vitro diagnosis of susceptibility to malignant hyperthermia.
Adnet PJ; Krivosic-Horber RM; Haudecoeur G; Adamantidis MM; Reyford GH; Imbenotte M; Cordonnier C
Br J Anaesth; 1990 Dec; 65(6):791-5. PubMed ID: 1702303
[TBL] [Abstract][Full Text] [Related]
7. In vitro diagnosis of susceptibility to malignant hyperthermia: evaluation of tests with halothane-caffeine, potassium chloride, suxamethonium and caffeine-suxamethonium.
Ording H; Skovgaard LT
Acta Anaesthesiol Scand; 1987 Jul; 31(5):462-5. PubMed ID: 3630591
[TBL] [Abstract][Full Text] [Related]
8. Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia?
Ellis FR; Halsall PJ; Hopkins PM
Br J Anaesth; 1992 Nov; 69(5):468-70. PubMed ID: 1467078
[TBL] [Abstract][Full Text] [Related]
9. Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
Gilly H; Musat I; Fricker R; Bittner RE; Steinbereithner K; Kress HG
Anesth Analg; 1997 Jul; 85(1):149-54. PubMed ID: 9212139
[TBL] [Abstract][Full Text] [Related]
10. 4-Chloro-m-cresol test--a possible supplementary test for diagnosis of malignant hyperthermia susceptibility.
Ording H; Glahn K; Gardi T; Fagerlund T; Bendixen D
Acta Anaesthesiol Scand; 1997 Sep; 41(8):967-72. PubMed ID: 9311392
[TBL] [Abstract][Full Text] [Related]
11. Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Ording H
Acta Anaesthesiol Scand; 1989 Jul; 33(5):405-8. PubMed ID: 2800978
[TBL] [Abstract][Full Text] [Related]
12. Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.
Wappler F; Roewer N; Köchling A; Scholz J; Löscher W; Steinfath M
Anesthesiology; 1996 Jun; 84(6):1280-7. PubMed ID: 8669667
[TBL] [Abstract][Full Text] [Related]
13. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study.
Schuster F; Metterlein T; Negele S; Kranke P; Muellenbach RM; Schwemmer U; Roewer N; Anetseder M
Anesth Analg; 2008 Sep; 107(3):909-14. PubMed ID: 18713904
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic malignant syndrome and malignant hyperthermia. In vitro comparison with halothane and caffeine contracture tests.
Krivosic-Horber R; Adnet P; Guevart E; Theunynck D; Lestavel P
Br J Anaesth; 1987 Dec; 59(12):1554-6. PubMed ID: 3426910
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
16. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.
Br J Anaesth; 1984 Nov; 56(11):1267-9. PubMed ID: 6487446
[TBL] [Abstract][Full Text] [Related]
17. Investigation of malignant hyperthermia in Denmark and Sweden.
Ording H; Ranklev E; Fletcher R
Br J Anaesth; 1984 Nov; 56(11):1183-90. PubMed ID: 6487440
[TBL] [Abstract][Full Text] [Related]
18. Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia.
Bendixen D; Ording H
Acta Anaesthesiol Scand; 1990 Nov; 34(8):658-61. PubMed ID: 2275327
[TBL] [Abstract][Full Text] [Related]
19. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
[TBL] [Abstract][Full Text] [Related]
20. 3,5-Di-t-butyl catechol is a potent human ryanodine receptor 1 activator, not suitable for the diagnosis of malignant hyperthermia susceptibility.
Lacava C; Michalek-Sauberer A; Kraft B; Sgaragli G; Sipos E; Höller C; Kress HG; Fusi F; Weigl LG
Pharmacol Res; 2012 Jul; 66(1):80-7. PubMed ID: 22480578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
